Compugen Ltd. (NASDAQ:CGEN) Receives $5.00 Average Price Target from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have been given a consensus recommendation of “Buy” by the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $5.00.

A number of brokerages recently weighed in on CGEN. Wall Street Zen downgraded shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Compugen in a report on Tuesday, August 4th. Weiss Ratings upgraded Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. Finally, Leerink Partners lowered their target price on Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, May 21st.

Institutional Investors Weigh In On Compugen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank Hapoalim BM bought a new position in Compugen during the fourth quarter worth about $37,000. Security National Bank of Sioux City Iowa IA bought a new stake in shares of Compugen in the fourth quarter valued at approximately $38,000. Franklin Resources Inc. purchased a new stake in shares of Compugen during the 2nd quarter valued at approximately $56,000. Calamos Advisors LLC purchased a new stake in shares of Compugen during the 1st quarter valued at approximately $63,000. Finally, Hillsdale Investment Management Inc. bought a new position in Compugen in the 1st quarter worth approximately $68,000. 12.22% of the stock is currently owned by institutional investors.

Compugen Stock Up 1.2%

CGEN stock opened at $2.59 on Friday. The firm has a market cap of $244.88 million, a PE ratio of 6.82 and a beta of 2.78. The business has a 50 day moving average of $2.42 and a 200-day moving average of $2.36. Compugen has a 12-month low of $1.29 and a 12-month high of $3.23.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a return on equity of 42.57% and a net margin of 47.56%.The business had revenue of $2.60 million for the quarter, compared to analyst estimates of $1.28 million. During the same period last year, the company posted ($0.08) earnings per share. On average, research analysts expect that Compugen will post -0.27 earnings per share for the current year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.